squamous cell carcinoma of thoracic esophagus
Conditions
Interventions
Control group A:The region of lymph node dissection for the upper and middle of thoracic esophageal cancer by two fields (E) (Abdominal + the expansion of dissection)
for the lower thoracic esophageal cancer by two fields (S) (Abdominal + standard dissection). No postoperative adjuvant chemotherapy.
Control group B:The region of lymph node dissection for the upper and middle of thoracic esophageal cancer by two fields (E) (Abdominal + the expansion of dissection)
for lower thoracic esophageal cancer by two fields (S) (Abdominal + standard dissection) Giving postoperative adjuvant chemotherapy for both.
Study group C:The region of lymph node dissection by two fields (T)( Abdominal + the entire dissection ). No postoperative adjuvant chemotherapy in control group.
Study group D:The region of lymph node dissection by two fields (T)(Abdominal + the entire dissection ). Giving postoperative adjuvant chemotherapy.
Study group E:The region of lymph node dissection by three fields (Abdominal + mediastinal + cervical ). No postoperative adjuvant chemotherapy.
Study group F:The region of lymph node dissection by three fields (Abdominal + mediastinal + cervical). Giving postoperative adjuvant chemotherapy.
Sponsors
Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
No minimum to 70 Years
Inclusion criteria
Inclusion criteria: 1. age=80; 3. Pathological diagnosis is squamous cell carcinoma of thoracic esophageal which is treated initially; 4. Clinical stage is c T 1 ~ 3 N0 ~ 1 according to the results of endoscopic ultrasonography; 5. Clinical stage is c T 1 ~ 3 N 0 ~ 1 M 0 according to the results of chest and abdomen CT; 6. Make neck ultrasonic to exclude metastasis of cervical lymph node; 7. The lesion is respectable according to the assessment of CT and EUS; 8. The preoperative evaluation of organ function is tolerant of surgery and chemotherapy; 9. The subject can understand and sign the informed consent form (ICF); 10. The following laboratory tests, made in 2 weeks before first medication, confirmed that bone marrow, liver and kidney function in line with the requirements to participate in research; 11. HB>=9.0g/L; ANC>=1.5*10^9/L; PLT>=100*10^9/L; TBIL<=1.5N; AST<=2.5N; ALT<=2.5N; PT<=1.5N, and APTT is in normal range; CRE<=1.5N.
Exclusion criteria
Exclusion criteria: 1. Cervical esophageal cancer and Non-squamous cell carcinoma of thoracic esophageal cancer; 2. Advanced Esophageal Cancer; 3. Prior malignancy in 5 years recently; 4. History of previous chest radiotherapy; 5. History of cardio-cerebral vascular accident in 6 months ately; 6. The subject can not understand and sign the informed consent form(ICF).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free survival;Overall survival; | — |
Countries
China
Contacts
Public ContactLin Peng
Outcome results
None listed